Form 4: Capricor Therapeutics Director Sells Shares

Capricor Therapeutics Director Karimah Es Sabar reported a sale of 7,529 shares of common stock on April 2, 2026, executed under a pre-established 10b5-1 trading plan.

Summary

• Karimah Es Sabar, a Director at Capricor Therapeutics, Inc., reported a transaction on April 2, 2026.
• The transaction involved the sale of 7,529 shares of common stock.
• The sale was executed at a price of $32.00 per share.
• This sale was conducted under a Rule 10b5-1 trading plan adopted in December 2025.
• Following the sale, the reporting person beneficially owns 7,529 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While a director sale can sometimes be perceived negatively, the execution under a Rule 10b5-1 plan suggests a pre-determined transaction rather than a reaction to adverse company news.

Negatives

• Director Karimah Es Sabar sold 7,529 shares of common stock at $32.00 per share.

Future Outlook

No specific future outlook or guidance is provided in this filing.

Industry Context

StockSavvy.ai notes that Form 4 filings, such as this one from Capricor Therapeutics, are standard disclosures for insider transactions. The execution of a Rule 10b5-1 plan indicates a pre-planned sale, often used by executives to diversify holdings or manage personal finances without implying negative sentiment about the company's prospects.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale by a director may be observed, but the Rule 10b5-1 plan mitigates concerns about insider trading. The remaining beneficial ownership by the director is noted.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Sale, Capricor Therapeutics, CAPR, Rule 10b5-1, Director Transaction